# Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure

> **NCT03860155** · PHASE1,PHASE2 · TERMINATED · sponsor: **RHEACELL GmbH & Co. KG** · enrollment: 5 (actual)

## Conditions studied

- Acute-On-Chronic Liver Failure

## Interventions

- **BIOLOGICAL:** allo-APZ2-ACLF

## Key facts

- **NCT ID:** NCT03860155
- **Lead sponsor:** RHEACELL GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-22
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-03-26
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Very slow recruitment of patients and the current COVID-19 pandemic situation.
- **Last updated:** 2021-11-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03860155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03860155, "Allogeneic ABCB5-positive Stem Cells for Treatment of Acute-on-Chronic Liver Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03860155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*